Bodaar, Kimberly http://orcid.org/0000-0003-0765-4237
Yamagata, Natsuko
Barthe, Anais
Landrigan, Jack
Chonghaile, Triona Ni
Burns, Melissa
Stevenson, Kristen E.
Devidas, Meenakshi
Loh, Mignon L.
Hunger, Stephen P. http://orcid.org/0000-0002-5492-3957
Wood, Brent
Silverman, Lewis B.
Teachey, David T. http://orcid.org/0000-0001-7373-8987
Meijerink, Jules P. http://orcid.org/0000-0002-6860-798X
Letai, Anthony http://orcid.org/0000-0002-1993-9013
Gutierrez, Alejandro http://orcid.org/0000-0002-0249-9007
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (CA193651)
V Foundation for Cancer Research
Article History
Received: 9 September 2019
Revised: 15 March 2022
Accepted: 24 March 2022
First Online: 11 April 2022
Competing interests
: SPH has received consulting fees from Novartis, honoraria from Amgen, Jazz Pharmaceuticals and Servier, and owns common stock in Amgen. LBS has received research funding from Novartis. DTT has served on advisory boards for BEAM Therapeutics, Janssen, and Sobi and receives research funding from Neoimmune Tech and BEAM Therapeutics. AL receives research support from AbbVie, AstraZeneca and Novartis, and is a cofounder and equity holder in Flash Therapeutics and Vivid Bioscience. AG receives research support from Astellas Pharma and is on an advisory board of Attivare Therapeutics. The authors have no other relevant conflicts of interest to disclose.